SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (16118)3/11/2005 4:55:20 PM
From: rkrw  Read Replies (1) | Respond to of 52153
 
No doubt ripe for a big placebo effect. Drop out rate was also high but they accounted for it with high enrollment. Note it's a phase II not III.

I agree on milnacipran chances. phase II was strongly significant. Something strange about their workings with frx has me a little nervous though.

Interestingly, endp's lidoderm patch is finding a lot of off label use in fms. Their patch is very amenable since it can be sliced up and placed on multiple problem spots. Apparently fms pain can be very site specific.



To: Biomaven who wrote (16118)3/12/2005 4:23:55 PM
From: Michael Young  Read Replies (1) | Respond to of 52153
 
I had an expert witness from Baylor in a case several years ago who firmly believed it was a fabricated disease. She was not a fan of Drs who promoted it is a diagnosis.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News